Commercial CVS obesity drug deal puts Lilly on equal footing with Novo BioPharma DiveThe agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.Metabolic & GLP-1Read full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioPharma Dive The agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: France ‘first EU country to cover obesity drugs’Next: GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’ Related Stories Commercial Moderna builds commercial muscle as new launches loom pharminent June 17, 2026 Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option pharminent June 8, 2026 Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity pharminent June 5, 2026
